Development of medical therapeutics in osteoarthritis: time for action to improve patient care
- PMID: 33715006
- PMCID: PMC8328507
- DOI: 10.1093/rheumatology/keab263
Development of medical therapeutics in osteoarthritis: time for action to improve patient care
Figures

Comment in
-
The IL-33/ST2 axis and vitamin D as a possible emerging therapeutic target in osteoarthritis.Rheumatology (Oxford). 2021 Aug 2;60(8):e300. doi: 10.1093/rheumatology/keab292. Rheumatology (Oxford). 2021. PMID: 33752232 No abstract available.
References
-
- Cross M, Smith E, Hoy D. et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73:1323–30. - PubMed
-
- March LC, Lo M, Arden C, Gates N, Leyland L, Hawker K, King GL. OARSI white paper- OA as a serious disease: Osteoarthritis Research Society International. https://oarsi.org/education/oarsi-resources/oarsi-white-paper-oa-serious....
-
- Hawker GA, Stewart L, French MR. et al. Understanding the pain experience in hip and knee osteoarthritis–an OARSI/OMERACT initiative. Osteoarthritis Cartilage 2008;16:415–22. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical